Latest Software Bridges Gap In Precision Medicine

University of California, San Francisco has recently unveiled a web based software platform that improves the precision of the medicines used in cancer treatment significantly. This new platform seamlessly integrates genomic analysis and testing, clinical and outcome data, and personalized treatment regimens. This integrates all of the features directly into the web based EMR systems. This project was a collaborative venture of the Genomic Medicine Initiative (GMI) by UCF and UCSF Helen Diller Family Comprehensive Cancer Center.

Kristen McCaleb, who is the program manager for the GMI said, “Many major medical institutions, including UCSF, have long had the science and the technology to generate genomic test results.” “The problem we’ve had is a lack of IT infrastructure to return those results to the clinicians who order the tests in a clearly actionable format. This new platform creates a doctor-friendly report that physicians can use to put genomics into the context of a patient’s clinical history, to receive guidance based on our institution’s best practices, to query for additional information—including outcomes of prior UCSF patients—and, ultimately, to provide better care for their patients,” he added.

Jonathan Hirsch, who is the Syapse president and founder, said that the tight integration with the web based EMR makes this platform very much powerful. “Genomics has the potential to dramatically improve patient care in oncology, but the full promise of precision medicine cannot be realized without a software platform that brings genomics to the point of care,” said Hirsch. “It is critical that genomic data be integrated with the patient’s medical history and presented to the clinician within the workflow of their EMR.”

The recommendations of the tumor board are recorded alongside the decision of the physician; and the clinical course of the patient will be continuously tracked, together with the resulting information that includes notes and summaries that are displayed to the doctor in an easy to understand graphical format. As the Syapse system is web based, the members of the Molecular Tumor Board and doctors will be able to query the test results of patients in real time, against the entries in the knowledge base of UCSF.

The integration of the software with the web based EMR systems allows increasing the effectiveness of the precision medicines that are used in treatment of cancer. Let us hope that this software together with the web based EMR systems will make cancer treatment more effective. Moreover, the last date for incorporating the latest ICD 10 codes in EMR is round the corner.